TrialAnnals of the rheumatic diseases2024

Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.

Thomas Dörner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.